Study Finds That Neuromyelitis Optica Patients Could Face Weakened Bones and Fractures
source: pixabay.com

Study Finds That Neuromyelitis Optica Patients Could Face Weakened Bones and Fractures

According to a story from Neurology Advisor, a recent study has found that patients living with neuromyelitis optica spectrum disorder (NMOSD) are at an increased risk of experiencing bone loss,…

Continue Reading Study Finds That Neuromyelitis Optica Patients Could Face Weakened Bones and Fractures

Those with Disabilities and Rare Medical Conditions in Canada are Excluded from Financial Relief During Covid-19

Kimberly Underhay Kimberly Underhay is a Canadian who has survived cancer. She has also been diagnosed with osteoarthritis and has to use a walker. Her disabilities have left her unable…

Continue Reading Those with Disabilities and Rare Medical Conditions in Canada are Excluded from Financial Relief During Covid-19

The Very First Treatment for Neurofibromatosis Type 1 Has Been Approved by the FDA

Neurofibromatosis  Neurofibromatosis is a rare condition that presents in different forms. Neurofibromatosis type one (NF1) causes tumors to grow on the plexiform neurofibromas, a type of nerve in the body. These tumors…

Continue Reading The Very First Treatment for Neurofibromatosis Type 1 Has Been Approved by the FDA
Amy Boland’s Last Option Was a Bispecific Antibody Drug for Lymphoma. It Worked.
source: pixabay.com

Amy Boland’s Last Option Was a Bispecific Antibody Drug for Lymphoma. It Worked.

  In a recent article that appeared in Science Magazine, Amy Boland described her twelve-year quest to find a cure for the cancer that invaded her lymph system. At first,…

Continue Reading Amy Boland’s Last Option Was a Bispecific Antibody Drug for Lymphoma. It Worked.
NDA to be Submitted for Potential Paroxysmal Nocturnal Hemoglobinuria Treatment
source: pixabay.com

NDA to be Submitted for Potential Paroxysmal Nocturnal Hemoglobinuria Treatment

According to a story from globenewswire.com, the biopharmaceutical company Apellis Pharmaceuticals, Inc. has announced that it is currently making plans to submit a New Drug Application (NDA) to the US…

Continue Reading NDA to be Submitted for Potential Paroxysmal Nocturnal Hemoglobinuria Treatment
Amy Boland’s Last Option Was a Bispecific Antibody Drug for Lymphoma. It Worked.
source: pixabay.com

Amy Boland’s Last Option Was a Bispecific Antibody Drug for Lymphoma. It Worked.

  In a recent article that appeared in Science Magazine, Amy Boland described her twelve-year quest to find a cure for the cancer that invaded her lymph system. At first,…

Continue Reading Amy Boland’s Last Option Was a Bispecific Antibody Drug for Lymphoma. It Worked.
Close Menu